According to AVEO Oncology 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -17.8571. At the end of 2021 the company had a P/E ratio of -2.73.
Year | P/E ratio | Change |
---|---|---|
2021 | -2.73 | -19.19% |
2020 | -3.37 | -133.51% |
2019 | 10.1 | -131.47% |
2018 | -32.0 | 599.64% |
2017 | -4.57 | 238.8% |
2016 | -1.35 | |
2014 | -0.8237 | |
2012 | -3.06 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Eli Lilly LLY | 143 | -902.42% | ๐บ๐ธ USA |
Amgen AMGN | 20.1 | -212.52% | ๐บ๐ธ USA |
Biogen BIIB | 11.7 | -165.41% | ๐บ๐ธ USA |
Regeneron Pharmaceuticals REGN | 25.8 | -244.27% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 13.7 | -176.50% | ๐บ๐ธ USA |
Merrimack Pharmaceuticals MACK | -134 | 651.93% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.